摘要
目的比较国产奥氮平(悉敏)与进口奥氮平(再普乐)治疗首发精神分裂症的临床疗效及安全性。方法将75例首发精神分裂症患者随机分为悉敏组(38例)和再普乐组(37例),治疗8周。用简明精神病量表(BPRS)、副反应量表(TESS)等评定疗效及不良反应。结果两组BPRS总分及各因子分治疗后均有明显下降,悉敏组有效率为80.6%,再普乐组有效率为80.0%,两组间疗效无显著差异。两组的不良反应均较轻微,组间比较无显著性差异。结论悉敏在治疗首发精神分裂症疗效和安全性方面和再普乐相当。
Objective To compare the efficacy and safety of domestic olanzapine（Ximin）in the treatment of first-episode schizophrenia with that of Zyprexa. Methods 75 patients with first-episode schizophrenia were divided into two groups who were treated with Ximin or Zyprexa respectively for 8 weeks. The Brief Psychiatric Rating Scale （BPRS） and Treatment Emergent Symptom Scale（TESS） were used to evaluate efficacy and adverse effect before and after treatment respectively. Results There were significant difference in the scores of BPRS before and after treatment in both groups. After 8-weeks treatment, the rate of the BPRS score decreased was 80.6% in the Ximin group and 80.0% in the Zyprexa group. There was no significant difference between two groups. The safety was similar between two groups. Conclusions The ximin would effectively improve the symptoms of the patients with schizophrenia; there were no significant difference on efficacy and safety between the ximin and Zyprexa.
出处
《神经疾病与精神卫生》
2006年第5期345-346,共2页
Journal of Neuroscience and Mental Health
